Common side effects of monoclonal antibodies include: Allergic reactions Chills Weakness Diarrhea Nausea Vomiting Rash Itching High blood glucose levels Cough Constipation Other side effects of monoclonal antibodies include: Shortness of breath Peripheral edema Headache Fever Muscle aches and pain Decreased appetite Increased triglyceride levels As with payments for administering other COVID-19 monoclonal antibodies, the separate Medicare payment amount of $450 per infusion of ACTEMRA applies to all hospitals not paid reasonable cost for furnishing these products consistent with the FDA approval or EUA. Monoclonal antibodies have been authorized for post-exposure prophylaxis, meaning they are used shortly after someone tests positive in order to prevent progression to severe disease. A one-time dose of two long-acting monoclonal antibodies reduced the risk of developing symptomatic COVID by 77% in comparison with placebo ( P < .001) in a randomized, double-blind, placebo . Monoclonal antibodies targeting the spike protein of the SARS-CoV-2 have yielded positive in vitro results. In: StatPearls [Internet]. The side effects of receiving any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the injection site. Providers and suppliers should use Q0245 and M0245 or M0246 to bill for administering bamlanivimab and etesevimab for PEP. On November 30, 2022, the, The patient has a positive COVID-19 test result, The patient is at high risk for progressing to severe COVID-19, hospitalization, or both, Immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, The ability to activate the emergency medical system (EMS), Refer to information from your state and local health authorities, REGEN-COV (casirivimab and imdevimab, administered together) (not currently authorized in any U.S region), Bamlanivimab and etesevimab, administered together(not currently authorized in any U.S region), Sotrovimab(not currently authorized in any U.S. region), Freestanding and hospital-based infusion centers, Entities with whom nursing homes contract to administer products, M0243 or M0244 when billing for the administration of the initial dose in a health care setting or the home, M0240 or M0241 when billing for the administration of any subsequent repeat doses in a health care setting or the home, M0245 when billing to administer in a health care setting, M0246 when billing to administer in the home or residence, Consistent with existing payment methodologies for the care setting where you provide the treatment, Casirivimab and imdevimab, to be administered together, Bamlanivimab and etesevimab, to be administered together, Tixagevimab co-packaged with cilgavimab, administered as 2 separate consecutive intramuscular injections, Bebtelovimab (if you got the product for free). The Medicare payment rate of approximately $450 for the administration of COVID-19 monoclonal antibody products will apply for the administration of ACTEMRA when you furnish it in accordance with the FDA approval or EUA. Effective January 1 of the year after that in which the EUA declaration ends: On May 6, 2021, CMS updated the Medicare payment rates for the administration of COVID-19 monoclonal antibody products. Swollen lips, face or throat. Monoclonal antibody therapy reduces deaths and hospitalizations in non-hospitalized patients with risk factors for severe disease progression. These antibodies were identified by analyzing convalescent plasma obtained from patients infected with COVID-19. Adults and children 12 years of age and olderAt first, 600 milligrams (mg) (two 300 mg injections) injected under the skin at different injection sites. Although the Food and Drug Administration gave these treatments like Regeneron emergency use authorization in 2020, the criteria for who is eligible to receive them has expanded. Discuss with your healthcare provider any symptoms you are experiencing after treatment. For many providers and suppliers, we also geographically adjustthis ratebased on where youfurnishthe service. bruising of the skin. [18]These variations have key mutations in the spike protein of the virus, and in some cases, such as the UK variant, make the virus 43to 82% more transmissible. Getting a vaccine is safer than getting COVID-19, and vaccination against COVID-19 is recommended for everyone 5 years of age and older. [22] The EUA for sotrovimab is for a single dose of 500 mg IV.[12]. Rarely, some patients will have what's called an "infusion reaction," where they have itching and throat tightness it looks similar to an allergic reaction. Monoclonal antibody therapy for COVID-19 is well tolerated with minimal risks. A benefit of casirivimab and imdevimab treatment has not been shown in people hospitalized due to COVID19. Benefits And Risks Of Administering Monoclonal Antibody Therapy For Coronavirus (COVID-19). Risk factors for severe and critically ill COVID-19 patients: A review. Get themost current geographically adjusted rates. Health care providers administering the infusions and injections of COVID-19 monoclonal antibody products will follow the same enrollment process as those administering the COVID-19 vaccines. Bamlanivimab (EUA issued November 9, 2020, EUA revoked April 16, 2021). Adverse events that have been observed have been injection site reactions with subcutaneous administration and transfusion-related reactions. Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, Tang X, Carmona Porquera EM, Kalari KR, Kandimalla KK. COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Check the Batch # on the vial. Evusheld therapy is made up of 1 injection of tixagevimab and 1 injection of cilgavimab, given separately into your muscle, one right after the other. Inpatient locations, such as inpatient hospitals, inpatient psychiatric hospitals, long-term care hospitals, and inpatient rehabilitation hospitals, would never qualify as the home or residence for purposes of HCPCS code M0221. CMS will continue to pay for COVID-19 monoclonal antibodies for post-exposure prophylaxis or for treatment of COVID-19 under the Medicare Part B vaccine benefit through the end of the calendar year in which the EUAdeclaration for COVID-19 drugs and biologicalsends. In most cases, your patients yearly Part B deductible and 20% co-insurance apply. But Regeneron Pharmaceuticals, maker of the only authorized, free monoclonal . Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens, such as viruses like SARS-CoV-2. Monoclonal antibody therapy is indicated for use in non-hospitalized patients with mild to moderate disease who have risk factors for progression to severe disease. Adverse Reactions As demonstrated above, monoclonal antibody therapy used in the treatment of outpatient COVID-19 in patients at risk for developing severe disease has the potential to decrease hospitalizations and mortality. Providers and suppliers may bill for the higher home payment rate when they furnish a COVID-19 monoclonal antibody product in a home or residence. This includes circumstancessuch as a Medicare patients permanent residence, temporary lodging (for example, hotel or motel, hostel, or homeless shelter), and homes or residences that have been made provider-based to the hospital during the COVID-19 PHE. Essentially, monoclonal antibody therapy for viral infection involves generating an antibody molecule type that reacts with the virus. A federal government website managed and paid for by the U.S. Centers for Medicare & Medicaid Services. For dates of service on or after August 15, only bill Medicare if you use commercially-purchased products. Talk to your healthcare provider if you experience any of the following in the days after monoclonal antibody treatment: Chills Diarrhea Fatigue Fever Muscle aches and pains Nausea Vomiting Cytokine Release Syndrome http://creativecommons.org/licenses/by-nc-nd/4.0/. The interprofessional healthcare team is also responsible for educating the patient on infection control measures. Monoclonal Antibodies to Treat Mild-to-Moderate COVID-19. Few cases of anaphylaxis have been reported. Management and preparedness for infusion and hypersensitivity reactions. On Jan. 24, the FDA announced it was no longer authorizing two COVID-19. They are exact copies of one . See theEUAfor more information. The federal government isnt purchasing VEKLURY. A recent study found that autoantibodies that existed before infection with SARS-CoV-2 may account for 20% or more of serious or fatal COVID-19 cases. Laboratory-made monoclonal antibodies help stimulate your own immune system. On January 26, 2023,the FDA announced that EVUSHELD isntcurrently authorized for emergency use in the U.S. People at risk of getting very sick from COVID-19 include: People who are age 65 or older. Monoclonal antibody therapy is a way of treating COVID-19 for people who have tested positive, have had mild symptoms for seven days or less, and are at high risk for developing more serious symptoms. While the initial data regarding monoclonal antibodies in the treatment of COVID-19 appears promising, at this time, thebulk ofthis data is preliminary and unpublished and has not been peer-reviewed. The highly contagious nature of the virus and its high potential for morbidity and mortality has overwhelmed hospital systems worldwide with hospitalizations and deaths. The FDA provides the information regarding proper dosing, storage, handling, and administration on the fact sheets issued for healthcare providers on the emergency use authorization for the three monoclonal antibodies that are currently available. Learn more about what to do if you are sick. Watch for Eli Lilly to release more information about future batch numbers. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Think of them as reinforcements from someone who had more time to build up defenses against COVID-19 which your immune system can benefit from earlier on. [23][24]Infusion-related reactions are characterized by flushing, fever/chills, back or abdominal pain, nausea/vomiting, pruritus, or skin rashes. The authorized dose for REGEN-COV for. StatPearls Publishing, Treasure Island (FL). In the clinical trial, molnupiravir was given to study participants in four capsules twice a day for five daysstarting within five days after patients experienced the first symptoms of COVID-19.. Side effects: Nausea is the most common side effect. For more information about viral variants in your area to help you make treatment decisions: Eligible administration sites must coordinate with their respective state or territorial health department to order these COVID-19 monoclonal antibodies: Get more information on the ordering process and reporting requirements. Most antibodies made by the human body are polyclonal, meaning that they are derived from multiple B lymphocyte lineages and have slightly different specificities for target antigens. [12][13][14], Viral Pathogenesis and Mechanism of Action, The novel coronavirus, SARS-CoV-2, is a positive-stranded RNA virus that is spread through respiratory droplets. [20], Sotrovimab, also called VIR-7831, is the only monoclonal antibody currently authorized for use. However, if the patient is only in that location temporarily (such as if your patient has a permanent home but is in a post-acute stay in a skilled nursing facility), the setting isnt considered a patients home or residence for this purpose, and you shouldnt bill for the higher at home HCPCS code M0221. These monoclonal antibodies are usually given as an intravenous (IV) infusion at . Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Brggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. Official websites use .govA Blood tests show even after three doses of Pfizer's vaccine, she has no detectable antibodies against Covid-19. Scientists have wondered if infection with SARS-CoV-2 could also result in the production of autoantibodies in people who didn't have them before they got sick. After binding the ACE2 receptor, the virus can gain entry to the cell, and viral replication can occur. ( This activity outlines the indications, actions, contraindications, and adverse events for monoclonal antibody therapy as a valuable treatment for outpatient COVID-19 infections. Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or. Vaccine recipients with preexisting immunity had systemic side effects at higher frequencies than those without preexisting immunity (fatigue, headache, chills, muscle pain, fever, and joint. The new rate reflects updated information about the costs involved in administering monoclonal antibody products for different types of providers and suppliersand the resources necessary to ensure providers administer the products safely and appropriately. COVID-19 Genomics UK (COG-UK) Consortium. Learn more about treatment guidelines and recommendations for using monoclonal antibody therapies. These antibodies are typically. ( Monoclonal Antibodies to Treat Mild-to-Moderate COVID-19 The FDA approved or authorized under EUA the following additional investigational monoclonal antibody therapies: ACTEMRA (tocilizumab) (EUA issued June, 24 2021, latest update December 21, 2022). Governor Ron De Santis touted it as an " early treatment for keeping people out of the hospital and reducing mortality.". Medicare will pay approximately $450 per infusion when 2 infusions are clinically necessary. There is an unpublished study for sotrovimab, which also shows a reduction in hospitalization and death. Side effects may occur from mAbs treatment including rash, diarrhea, nausea, dizziness and pruritis (itchy skin). Therefore, youmay not administerREGEN-COVfor treatment or post-exposure prevention of COVID-19 under the EUA until further notice. The word "monoclonal" refers to the fact that the antibodies created in the laboratory are clones. The expert clinicians agree that my best hope is Humira (generic name, adalimumab), one in a class of drugs known as monoclonal antibodies that block the immune system proteins that make joints . lock The goal of this therapy is to help prevent hospitalizations, reduce viral loads, and lessen symptom severity. Monoclonal antibodies may block the SARS-CoV-2 virus from attaching to human cells and help neutralize the virus (meaning they stop the virus from replicating). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent in COVID-19, has created a global pandemic and overwhelmed hospital systems globally. The . Regeneron, which is a brand name for two monoclonal antibodies that are given simultaneously, is what is being used in the Florida monoclonal antibody treatment centers. More Information about Payment for Infusion & IV Injection at Home. We allow Medicare-enrolled immunizers including, but not limited to, pharmacies working with the U.S., infusion centers, and home health agencies to bill directly and get direct payment from the Medicare Program for vaccinating Medicare SNF residents. Secure .gov websites use HTTPSA This rate applies to all providers and suppliers not paid reasonable cost for furnishing these products. On January 24, 2022, the FDA announced that, Sotrovimab (EUA issued May 26, 2021, latest update February 23, 2022). An EUA for sotrovimab for treatment of COVID-19. The federal government isn't distributing the following products; you may purchase them through typical purchasing channels: Medicare will cover and pay for the administration of monoclonal antibodyinfusions and injectionsused for post-exposure prophylaxis or treatment of COVID-19(when furnished consistent with their respective approvals or EUAs) the same way it covers and pays for COVID-19 vaccines until the end of the calendar year in which the EUA declaration for COVID-19 drugs and biologicals ends. In August, Florida launched the first mobile unit to provide monoclonal antibody treatments for coronavirus patients. Dizziness or low blood pressure. See Limitations of Authorized Use. Effective for services furnished on or after May 6, 2021, the Medicare payment rate for administering COVID-19 monoclonal antibody products through infusion in a patients home or residence is approximately $750. For outpatients, the treatment is a three-day course of infusions that must be initiated within seven days of symptom onset. It's important to note that the pill is meant to be taken after you've experienced COVID-19 symptoms. Medicare will establish codes and rates for administering new products as the FDA approves or authorizes each product. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y, Fullerton KE. [2][3][4]At this time, however, there is minimal data that suggests these therapies improve outcomes. In general, the more common side effects caused by monoclonal antibody drugs include: Allergic reactions, such as hives or itching Flu-like signs and symptoms, including chills, fatigue, fever, and muscle aches and pains Nausea, vomiting Diarrhea Skin rashes Low blood pressure Serious side effects Providers and suppliers who administer REGEN-COV for PEP should use M0243 or M0244 for administering the first dose and M0240 or M0241 for administering subsequent repeat doses. lock Effective for services furnished on or after February 11, 2022, the Medicare payment rate for administering COVID-19 monoclonal antibody products through IV injection (such as bebtelovimab) in a patients home or residence is approximately $550.50. Flu-like symptoms (fever, sweating, chills, cough, sore throat, headache or muscle pain) Upset stomach (nausea, vomiting or diarrhea) Itching, swelling, rash or hives. Evusheld is the only non-vaccine with emergency use authorization (EUA) from the FDA to prevent infection from COVID-19 before you're exposed to the virus. [27], Analysis by Stokes et al. Monoclonal antibodies, like most medications, carry risks and side effects that you and your doctor need to weigh against any possible benefits. REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among. This is a kind of protein that can lock onto and disable a virus or "antigen." A successful antibody does usually one of two things: It blocks the virus from entering cells, and. The cause wasdemonstrated to be anovel coronavirus, called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Typical side effects include pain at the injection site, fever, fatigue, headache, muscle pain, chills and diarrhoea. We geographically adjust the rate based on where you furnish the service. Inflammation and problems with the immune system can also happen. As a result, CMS issued a new product code for REGEN-COV of 600 mg (Q0240) and 2 new codes for the administration of repeat doses of REGEN-COV (M0240/M0241). The FDA strongly recommends IV infusion except for when IV infusion is not available or would lead to a delay in treatment. [9][10][11]The only monoclonal antibody currently authorized for emergency use in the United States by the FDA is sotrovimab. Prajapat M, Handa V, Sarma P, Prakash A, Kaur H, Sharma S, Bhattacharyya A, Kumar S, Sharma AR, Avti P, Medhi B. Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. For example, Medicare will pay 95% of AWP for COVID-19 vaccines provided in the physician office setting, and pay hospital outpatient departments at reasonable cost for COVID-19 vaccines. Getprovider enrollmentinformation. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. COVID-19 vaccines protect against the SARS-CoV-2 virus only, so it's still important to keep yourself healthy and well. Inpatient locations, such as inpatient hospitals, inpatient psychiatric hospitals, long-term care hospitals, and inpatient rehabilitation hospitals, would never qualify as the home or residence for purposes of HCPCS codes M0241, M0244, M0246, M0248, or M0223. CMS pays for tocilizumab based on the number of units administered, so you should include the total number of units administered on the claim per day. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on healthcare facilities, and even save lives. Note: On April 16, 2021, the FDA revoked the EUA for bamlanivimab when administered alone. To ensure access during the PHE, Medicare covers and pays for COVID-19 monoclonal antibodies under the COVID-19 vaccine benefit. In the same patient population, mortality was also greatly increased compared to younger healthy individuals (19.5% vs. Typically, monoclonal antibodies are given to higher-risk patients who have mild to moderate symptoms from a COVID-19 infection. Lenz HJ. Millions of vaccinated people have experienced side . Not many people have received bebtelovimab. Vaccines prevent progression for a larger part of the population. means youve safely connected to the .gov website. Healthcare providers should also be aware of the resistance of certain variants of the SARS-CoV-2 virus. Sotrovimab targets a highly conserved epitope of the RBD that is present across the entire family of SARS-like coronaviruses. Long descriptor: Injection, bamlanivimab-xxxx, 700 mg, Long Descriptor: Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring, Short Descriptor: Bamlanivimab-xxxx infusion, RegeneronsAntibody REGEN-COV (casirivimab and imdevimab)(ZIP), Note: This product isnt currently authorized[1], Note: While the product EUA was originally issued on November 21, 2020, these product and administration codes are effective July 30, 2021, Long descriptor: Injection, casirivimab and imdevimab, 600 mg, Short descriptor: Casirivi and imdevi 600 mg, Long Descriptor: Intravenous infusion or subcutaneous injection,casirivimab and imdevimab includes infusion or injection,and post administration monitoring, subsequent repeat doses, Short Descriptor:Casirivi and imdevi repeat, RegeneronsAntibody REGEN-COV (casirivimab and imdevimab) (ZIP), Long Descriptor: Intravenous infusion or subcutaneous injection,casirivimab and imdevimab includes infusion or injection,and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency,subsequent repeat doses, Short Descriptor:Casirivi and imdevi repeat hm, Long descriptor:Injection, casirivimab and imdevimab, 2400 mg, Short descriptor:Casirivimab and imdevimab, Long descriptor: Injection, casirivimab and imdevimab, 1200 mg, Short descriptor: Casirivi and imdevi 1200 mg, Long Descriptor: Intravenous infusion or subcutaneous injection,casirivimab and imdevimab includes infusion or injection,and post administration monitoring, Short Descriptor:Casirivi and imdevi inj, Regenerons Antibody REGEN-COV (casirivimab and imdevimab) (ZIP), November 21, 2020 TBDNote: While the product EUA was issued on November 21, 2020, this administration code is effective May 6, 2021, Long descriptor: Injection, casirivimab and imdevimab, 2400 mg, Short descriptor: Casirivimab and imdevimab, Long Descriptor: Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiarys home that has been made provider-based to the hospital during the COVID-19 public health emergency, Short Descriptor: Casirivi and imdevi inj hm, Eli Lilly and CompanysAntibody Bamlanivimab and Etesevimab, (ZIP), Long descriptor: Injection, bamlanivimab and etesevimab, 2100 mg, Short descriptor: Bamlanivimab and etesevima, Long Descriptor: Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring, Short Descriptor: Bamlan and etesev infusion, Eli Lilly and Companys Antibody Bamlanivimab and Etesevimab, (ZIP), February 9, 2021 (reissued on February 25, 2021) TBD, Note: While the product EUA was issued on February 9, 2021, this administration code is effective May 6, 2021, Long Descriptor: Injection, bamlanivimab and etesevimab, 2100 mg, Short Descriptor: Bamlanivimab and etesevima, Long Descriptor: Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiarys home that has been made provider-based to the hospital during the COVID-19 public health emergency, Short Descriptor: You might have both United States Government (USG)-purchased and commercial product in your inventory. When the drug enters your bloodstream, it blocks the ability of the SARS-CoV-2 virus to . Monoclonal antibodies are given intravenously (injected into a vein). J0248 represents 1mg, and you should report units to reflect the dosage you administered for each patient. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. The emergency use authorization(EUA) for sotrovimab is for use in non-hospitalized patients 12 years or older, weighing more than 40 kg, with mildor moderate symptoms, who have one or more risk factors for progression to severe disease. The U.S. Food and Drug Administration has authorized treatments that have already been taken by millions of people, reducing their COVID-19 symptoms and keeping many of them out of the hospital. In these situations, use the following HCPCS codes to bill for casirivimab and imdevimab: The September 16, 2021, revised EUA for bamlanivimab and etesevimab allows for its use for PEP in certain adult and pediatric patients. Given that, a TGC . Dolgin E. 'Super-antibodies' could curb COVID-19 and help avert future pandemics. Monoclonal antibodies are intended for the treatment of outpatient mild-moderate COVID-19 infections in patients with risk factors for progression to severe disease. It works by stopping SARS-CoV-2 from spreading in the body. Medicare will only cover and pay for bamlanivimab (administered alone) if it was furnished, consistent with the terms of the EUA, between November 10, 2020 - April 16, 2021. Monoclonal antibodies, . If you administer these COVID-19 monoclonal antibody products in Medicare patients in traditional health care locations (for example, a hospital outpatient infusion clinic or freestanding infusion clinic), continue to bill HCPCS code M0220, as applicable. Medicare also pays for treatment to address major complications: For COVID-19 monoclonal antibody products administered before May 6, 2021, the Medicare payment rate is approximately $310. Bamlan and etesev infus home, Note: This product isnt currently authorized[6], Long descriptor: Injection, sotrovimab, 500 mg, Long Descriptor: Intravenous infusion, sotrovimab, includes infusion and post administration monitoring, Long Descriptor: Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiarys home that has been made provider-based to the hospital during the COVID-19 public health emergency, Short Descriptor: Sotrovimab inf, home admin, Genentechs Antibody ACTEMRA (tocilizumab), Long descriptor: Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg, Short descriptor: Tocilizumab for COVID-19, Long Descriptor: Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose, Short Descriptor: Adm Tocilizu COVID-19 1st, Long descriptor: Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose, Short descriptor: Adm Tocilizu COVID-19 2nd, AstraZenecas Antibody EVUSHELD (tixagevimab and Cilgavimab)Note: This product isnt currently authorized[8], Long descriptor: Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg, Long descriptor: Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring, Long descriptor: Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiarys home that has been made provider-based to the hospital during the covid-19 public health emergency, Short descriptor: Tixagev and cilgav inj hm, Long Descriptor:Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg, Short Descriptor:Tixagev and cilgav, 600mg, Long descriptor:Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring, Long descriptor:Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiarys home that has been made provider-based to the hospital during the covid-19 public health emergency, Short descriptor:Tixagev and cilgav inj hm, Eli Lilly and Companys Antibody Bebtelovimab (PDF), Note: This product isnt currently authorized[7], Long descriptor:Injection, bebtelovimab, 175 mg, Long Descriptor:Intravenous injection, bebtelovimab, includes injection and post administration monitoring, Long Descriptor:Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiarys home that has been made provider-basedto the hospital during the covid-19 public health emergency, Short Descriptor: Bebtelovimab injection home.